“Rilpivirine is better tolerated, less toxic and more durable than efavirenz when used as part of a first-line antiretroviral regimen, investigators from Italy report in HIV Medicine.
Although the two drugs showed similar virological efficacy, people treated with efavirenz were significantly more likely than individuals taking rilpivirine to stop taking a drug because of toxicity, intolerance or to make a proactive treatment switch in the first two years after antiretroviral therapy (ART) initiation.”
For more, click here.